SCHEMBL443220

SCHEMBL443220

O=C(O)CCN1CCCC1=O

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.53
KMT2A Q03164 5/20 0.51
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.46
POLB P06746 3/20 0.46
PIK3CD O00329 1/20 0.46
MEN1 O00255 2/20 0.45
KDM4E B2RXH2 2/20 0.45
MAPT P10636 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PKM P14618 1/20 0.45
BLM P54132 1/20 0.44
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KDM4C Q9H3R0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7328278 0.94 KMT2A (0.50) TSHRKMT2ALMNAHTTPOLB
SCHEMBL14828748 0.92 KMT2A (0.53) TSHRKMT2ALMNAHTTPOLB
SCHEMBL855306 0.89 TSHR (0.50) TSHRKMT2ALMNAHTTPOLB
SCHEMBL7504798 0.88 KMT2A (0.51) TSHRKMT2ALMNAPOLBMEN1
SCHEMBL2944990 0.87 TSHR (0.49) TSHRKMT2AHTTMEN1NPC1
SCHEMBL19513862 0.85 TSHR (0.47) TSHRKMT2AMEN1GAANPC1
SCHEMBL9151143 0.85 TSHR (0.47) TSHRKMT2AMEN1GAANPC1
SCHEMBL27389883 0.85 KMT2A (0.50) TSHRKMT2ALMNAHTTPOLB
SCHEMBL7416853 0.85 TSHR (0.47) TSHRKMT2AMEN1GAANPC1
SCHEMBL19513822 0.85 TSHR (0.47) TSHRKMT2AMEN1GAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522596-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X Discovery Limited (GB) 2025-03-19 EP disclosed
CN-119497712-A Indane derivatives as MALT1 inhibitors 希四克斯探索有限公司 2025-02-21 CN disclosed
EP-4081299-B1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2024-09-25 EP disclosed
US-20240132513-A1 BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO, INC. 2024-04-25 US disclosed
WO-2024039886-A1 BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO, INC. (US) 2024-02-22 WO disclosed
WO-2023218203-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2023-11-16 WO disclosed
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-11-09 US disclosed
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-11-09 US disclosed
US-20230330254-A1 ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2023-10-19 US disclosed
US-20230330254-A1 ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2023-10-19 US disclosed
EP-0807267-B1 CROSSLINKED POLYMERS CONTAINING URETHANE GROUPS NOVARTIS AG (CH) 2000-03-01 EP disclosed
WO-1999006397-A2 PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ABBOTT LABORATORIES (US) 1999-02-11 WO disclosed
EP-0885215-A1 NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS Abbott Laboratories (US) 1998-12-23 EP disclosed
US-5807927-A POLYVINYL ACETALS MODIFIED BY ISOCYANATO ACRYLATES; CONTACT LENSES CIBA VISION CORPORATION (US) 1998-09-15 US disclosed
CN-1172534-A Crosslinked polymers containing urethane groups CIBA GEIGY AG (CH) 1998-02-04 CN disclosed
EP-0807267-A1 CROSSLINKED POLYMERS CONTAINING URETHANE GROUPS Novartis AG (CH) 1997-11-19 EP disclosed
WO-1997030045-A1 NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS ABBOTT LABORATORIES (US) 1997-08-21 WO disclosed
WO-1996024073-A1 CROSSLINKED POLYMERS CONTAINING URETHANE GROUPS NOVARTIS AG (CH) 1996-08-08 WO disclosed
US-4543216-A REACTING A VINYL BENZYL HALIDE WITH AN AMINO ACID OR AMINO SULFONIC ACID NIPPON PAINT CO., LTD. (JP) 1985-09-24 US disclosed
US-4452746-A TO MODIFY PROPERTIES OF HIGH MOLECULAR WEIGHT COMPOUNDS NIPPON PAINT CO., LTD. (JP) 1984-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS GIPR, GLP1R, GCGR TSHR 140/4885KMT2A 3040/4885LMNA 3629/4885
US-20230330254-A1 ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF GLP1R, GIPR, GCGR TSHR 127/4885KMT2A 1978/4885LMNA 3408/4885
US-20240132513-A1 BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT GABRA5, GRM5, GABRB1 TSHR 779/4885KMT2A 1076/4885LMNA 1853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.